Cross-Sector entity
Of the tracked stories, 2 of 2 also mention Auvelity, the most common co-covered peer. Coverage clusters in fda-approval, which accounts for 1 of those 2, with the remainder spread across 1 other category. The tracked stories average 2 original sources each.
2 verified stories tracked
Last mentioned: Jul 7, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention Auvelity, the most common co-covered peer. Coverage clusters in fda-approval, which accounts for 1 of those 2, with the remainder spread across 1 other category. The tracked stories average 2 original sources each. Axsome Therapeutics appears in 2 tracked Cross-Sector stories from July 7, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Axsome Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Moderna flu vaccine PDUFA date
FDA target decision deadline for Moderna's mRNA-based seasonal influenza vaccine.
Axsome full-year 2025 results
Annual revenue more than doubles to $617.1 million, with Auvelity net product revenue up 68% year over year.
Revolution Medicines mid-2025 data readout
RMC-6236 shows nearly 90% tumor response in an early-phase pancreatic cancer study, driving stock surge.
A trio of biotech stocks generated staggering H1 2026 returns, with Revolution Medicines leading at +230%. Axsome Therapeutics' revenue more than doubled to $617.1 million, underscoring a market rotation into catalyst-driven, high-growth healthcare plays amid macro uncertainty.
Three biotech stocks trounced the broader market in H1 2026 on powerful clinical and regulatory catalysts. Moderna's upcoming FDA decision for its flu vaccine could sustain momentum, while Revolution Medicine's 90% tumor response data and Axsome's $617M revenue underscore the sector's upside.
Source: The Motley Fool · Adria Cimino
